Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, RDY, BGNE, CI, Alpine Immune Sciences, and represent 25.52% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: BGNE, RNA, CRBP, CNTA, AVTE, MOR, KRYS, TVTX, INZY, ELEV.
- Started 28 new stock positions in VTYX, AGIO, NARI, MRNS, AVRO, KRYS, OCUL, OLMA, ELVN, SGMT.
- Reduced shares in these 10 stocks: , Inhibrx, GPCR, RCKT, LEGN, Alpine Immune Sciences, BHVN, LNTH, , CLDX.
- Sold out of its positions in APLS, CABA, CPRX, EYPT, Gracell Biotechnologies, IGMS, ImmunoGen, Inhibrx, Kinnate Biopharma, LNTH.
- Exome Asset Management was a net buyer of stock by $7.3M.
- Exome Asset Management has $117M in assets under management (AUM), dropping by 15.47%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 53 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Eli Lilly & Co. (LLY) | 6.5 | $7.5M | 9.7k | 777.96 |
|
|
Dr Reddys Labs Adr (RDY) | 5.4 | $6.3M | -4% | 86k | 73.35 |
|
Beigene Sponsored Adr (BGNE) | 4.9 | $5.8M | +187% | 37k | 156.39 |
|
Cigna Corp (CI) | 4.8 | $5.6M | 15k | 363.19 |
|
|
Alpine Immune Sciences | 4.0 | $4.6M | -32% | 117k | 39.64 |
|
Tg Therapeutics (TGTX) | 3.0 | $3.5M | +13% | 230k | 15.21 |
|
Avidity Biosciences Ord (RNA) | 3.0 | $3.4M | NEW | 135k | 25.52 |
|
Corbus Pharmaceuticals Hldgs Com New (CRBP) | 3.0 | $3.4M | NEW | 88k | 39.24 |
|
Dex (DXCM) | 2.9 | $3.4M | 25k | 138.70 |
|
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.7 | $3.1M | NEW | 275k | 11.30 |
|
Celldex Therapeutics Com New (CLDX) | 2.6 | $3.0M | -36% | 71k | 41.97 |
|
Geron Corporation (GERN) | 2.5 | $2.9M | +45% | 887k | 3.30 |
|
Aerovate Therapeutics (AVTE) | 2.5 | $2.9M | NEW | 99k | 29.57 |
|
Morphosys Sponsored Ads (MOR) | 2.4 | $2.8M | NEW | 155k | 18.14 |
|
Travere Therapeutics (TVTX) | 2.4 | $2.8M | +331% | 363k | 7.71 |
|
Krystal Biotech (KRYS) | 2.2 | $2.6M | NEW | 15k | 177.93 |
|
Intuitive Surgical Com New (ISRG) | 2.2 | $2.5M | 6.4k | 399.09 |
|
|
Tarsus Pharmaceuticals (TARS) | 2.1 | $2.4M | -21% | 66k | 36.35 |
|
Madrigal Pharmaceuticals (MDGL) | 1.8 | $2.1M | -40% | 7.9k | 267.04 |
|
Inozyme Pharma (INZY) | 1.8 | $2.1M | NEW | 273k | 7.66 |
|
Rhythm Pharmaceuticals (RYTM) | 1.7 | $2.0M | -36% | 46k | 43.33 |
|
Insmed Com Par $.01 (INSM) | 1.7 | $1.9M | +16% | 72k | 27.13 |
|
Elevation Oncology (ELEV) | 1.6 | $1.9M | NEW | 369k | 5.13 |
|
EXACT Sciences Corporation (EXAS) | 1.6 | $1.8M | NEW | 27k | 69.06 |
|
Cytokinetics Com New (CYTK) | 1.6 | $1.8M | -25% | 26k | 70.11 |
|
Regenxbio Inc equity us cm (RGNX) | 1.5 | $1.8M | NEW | 85k | 21.07 |
|
Biogen Idec (BIIB) | 1.5 | $1.8M | 8.2k | 215.63 |
|
|
Ocular Therapeutix (OCUL) | 1.5 | $1.8M | NEW | 194k | 9.10 |
|
Agios Pharmaceuticals (AGIO) | 1.5 | $1.8M | NEW | 60k | 29.24 |
|
Natera (NTRA) | 1.5 | $1.7M | 19k | 91.46 |
|
|
Penumbra (PEN) | 1.4 | $1.6M | -14% | 7.4k | 223.18 |
|
Guardant Health (GH) | 1.4 | $1.6M | NEW | 79k | 20.63 |
|
Olema Pharmaceuticals (OLMA) | 1.4 | $1.6M | NEW | 143k | 11.32 |
|
Arrowhead Pharmaceuticals (ARWR) | 1.4 | $1.6M | NEW | 56k | 28.60 |
|
Bridgebio Pharma (BBIO) | 1.3 | $1.5M | -25% | 49k | 30.92 |
|
Terns Pharmaceuticals (TERN) | 1.3 | $1.5M | NEW | 228k | 6.56 |
|
Marinus Pharmaceuticals Com New (MRNS) | 1.3 | $1.5M | NEW | 163k | 9.04 |
|
Inari Medical Ord (NARI) | 1.2 | $1.4M | NEW | 30k | 47.98 |
|
Quanterix Ord (QTRX) | 1.2 | $1.4M | NEW | 60k | 23.56 |
|
Intra Cellular Therapies (ITCI) | 1.2 | $1.4M | -28% | 20k | 69.20 |
|
Shockwave Med | 1.1 | $1.3M | 4.0k | 325.63 |
|
|
Vyne Therapeutics (VYNE) | 1.1 | $1.3M | +251% | 415k | 3.07 |
|
Regulus Therapeutics (RGLS) | 1.0 | $1.2M | +125% | 403k | 2.88 |
|
Q32 Bio (QTTB) | 0.9 | $1.1M | NEW | 65k | 17.04 |
|
Zai Lab Adr (ZLAB) | 0.9 | $1.0M | NEW | 65k | 16.02 |
|
Enliven Therapeutics (ELVN) | 0.9 | $1.0M | NEW | 58k | 17.59 |
|
Ventyx Biosciences (VTYX) | 0.8 | $902k | NEW | 164k | 5.50 |
|
Ultragenyx Pharmaceutical (RARE) | 0.7 | $831k | NEW | 18k | 46.69 |
|
I Mab Sponsored Ads (IMAB) | 0.5 | $606k | NEW | 326k | 1.86 |
|
Adagene Ads (ADAG) | 0.4 | $435k | NEW | 155k | 2.80 |
|
Sagimet Biosciences Com Ser A (SGMT) | 0.3 | $330k | NEW | 61k | 5.42 |
|
Pacific Biosciences of California (PACB) | 0.2 | $282k | 75k | 3.75 |
|
|
Avrobio Ord (AVRO) | 0.1 | $78k | NEW | 61k | 1.28 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024